Apple Watch AFib feature gets new FDA seal of approval

Share via:


The Apple Watch AFib feature – which detects abnormal heartbeat patterns indicative of atrial fibrillation – has received a new tick of approval from the US Food and Drug Administration (FDA). Doctors have already credited the health feature with saving lives.

While the FDA had previously granted clearance for AFib detection, that was a limited endorsement …

The Apple Watch previously had FDA ‘clearance’

When the FDA first cleared Apple to include atrial fibrillation detection by the Apple Watch, that was the lowest hurdle. Specifically, the 510(k) clearance granted to Apple effectively said that the device is “substantially equivalent” to some existing device.

In other words, there were already existing optical pulse oximeters which worked in the same way as the one fitted to the Apple Watch, and those had already been shown to detect AFib.

Since usage of those earlier devices was already permitted, then the new device is effectively grandfathered in by a 510(k) clearance.

Now qualifies under MDDT program

The FDA has now announced that the Apple Watch AFib feature has now qualified as a Medical Device Development Tool (MDDT).

It says that this is the first ever digital health tech to qualify under the program.

The FDA is announcing the qualification of a new tool to assess atrial fibrillation (a type of arrhythmia, or abnormal heartbeat) burden estimates within clinical studies through the Medical Device Development Tools (MDDT) program.

The Apple Atrial Fibrillation History Feature is the first digital health technology qualified under the MDDT program, providing a non-invasive way to check estimates of atrial fibrillation (AFib) burden within clinical studies.

What does this mean?

It means researchers carrying out clinical studies into atrial fibrillation are now allowed to rely on Apple Watch AFib data as part of their findings.

Specifically, an Apple Watch can now be used to determine the severity of AFib (known as the AFib burden) in order to determine whether treatment is needed, and then to measure the effectiveness of that treatment afterwards.

The MDDT qualification determines that the device creates “scientifically plausible measurements.” Effectively, the FDA is stating that it is sufficiently confident in the reliability of the feature to determine its results safe to use in research studies.

I’ve previously argued that AFib History is the quiet beginning of a huge Apple Health revolution.

Via MyHealthyApple and Macrumors. Image: Apple.

FTC: We use income earning auto affiliate links. More.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Apple Watch AFib feature gets new FDA seal of approval


The Apple Watch AFib feature – which detects abnormal heartbeat patterns indicative of atrial fibrillation – has received a new tick of approval from the US Food and Drug Administration (FDA). Doctors have already credited the health feature with saving lives.

While the FDA had previously granted clearance for AFib detection, that was a limited endorsement …

The Apple Watch previously had FDA ‘clearance’

When the FDA first cleared Apple to include atrial fibrillation detection by the Apple Watch, that was the lowest hurdle. Specifically, the 510(k) clearance granted to Apple effectively said that the device is “substantially equivalent” to some existing device.

In other words, there were already existing optical pulse oximeters which worked in the same way as the one fitted to the Apple Watch, and those had already been shown to detect AFib.

Since usage of those earlier devices was already permitted, then the new device is effectively grandfathered in by a 510(k) clearance.

Now qualifies under MDDT program

The FDA has now announced that the Apple Watch AFib feature has now qualified as a Medical Device Development Tool (MDDT).

It says that this is the first ever digital health tech to qualify under the program.

The FDA is announcing the qualification of a new tool to assess atrial fibrillation (a type of arrhythmia, or abnormal heartbeat) burden estimates within clinical studies through the Medical Device Development Tools (MDDT) program.

The Apple Atrial Fibrillation History Feature is the first digital health technology qualified under the MDDT program, providing a non-invasive way to check estimates of atrial fibrillation (AFib) burden within clinical studies.

What does this mean?

It means researchers carrying out clinical studies into atrial fibrillation are now allowed to rely on Apple Watch AFib data as part of their findings.

Specifically, an Apple Watch can now be used to determine the severity of AFib (known as the AFib burden) in order to determine whether treatment is needed, and then to measure the effectiveness of that treatment afterwards.

The MDDT qualification determines that the device creates “scientifically plausible measurements.” Effectively, the FDA is stating that it is sufficiently confident in the reliability of the feature to determine its results safe to use in research studies.

I’ve previously argued that AFib History is the quiet beginning of a huge Apple Health revolution.

Via MyHealthyApple and Macrumors. Image: Apple.

FTC: We use income earning auto affiliate links. More.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Australian government drops misinformation bill

The Australian government has withdrawn a bill that...

Latin America fintech will be a market to watch...

Midway through 2024, Mike Packer, a partner at...

Reserve Bank of India expanding cross-border payments platform

According to the Atlantic Council, 134 countries are...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!